Search results for "Antiandrogens"

showing 7 items of 7 documents

Carcinoma of the prostate. Guidelines for treatment: the role of antiandrogens.

1990

Our preliminary experience shows that flutamide is effective in patients with stage C or D prostate cancer. Local and distant response rates are comparable to those obtained with "classic" hormone therapy. Libido and sexual potency generally are unaffected. Palliation of symptoms, which is frequent, is usually accompanied by improved performance status and quality of life. Side effects are slight or moderate, but elevated transaminase levels in patients with borderline liver insufficiency are possible.

OncologyMalemedicine.medical_specialtyAntiandrogensmedicine.medical_treatmentUrologyImidazolidinesGeneral Biochemistry Genetics and Molecular BiologyFlutamideProstate cancerchemistry.chemical_compoundHistory and Philosophy of ScienceProstateInternal medicinemedicineCarcinomaHumansLibidobusiness.industryGeneral NeuroscienceCarcinomaImidazolesProstatic NeoplasmsAndrogen Antagonistsmedicine.diseaseFlutamidemedicine.anatomical_structurechemistryElevated transaminasesHormone therapybusinessAnnals of the New York Academy of Sciences
researchProduct

Re: Does Oral Antiandrogen Use Before Leuteinizing Hormone-Releasing Therapy in Patients with Metastatic Prostate Cancer Prevent Clinical Consequence…

2010

Oh et al report their experience with 1566 metastatic prostate cancer patients treated with luteinising hormone-releasing hormone (LHRH) agonists in the area of Boston, Massachusetts, USA. Of these patients, 79.5% were given antiandrogens (bicalutamide, flutamide, or nilutamide) before the first LHRH agonist dose. The remaining patients (20.5%) did not receive antiandrogens. In all patients, complications appearing within 30 d and attributable to a flare phenomenon (fractures, spinal cord compression, bladder outlet obstruction, exacerbation of pain) were assessed retrospectively. Such complications were extremely rare ( or =7 d before starting the LHRH analogues) made no difference.The aut…

Oncologymedicine.medical_specialtyBicalutamideAntiandrogensmedicine.drug_classbusiness.industryUrologyUrologyurologic and male genital diseasesAntiandrogenmedicine.diseaseFlutamidechemistry.chemical_compoundProstate cancerchemistryInternal medicineNilutamidemedicineAntiandrogen Therapybusinesshormones hormone substitutes and hormone antagonistsLeuteinizing hormonemedicine.drugEuropean Urology
researchProduct

Pharmacological treatment of patients with paraphilic disorders and risk of sexual offending: An international perspective

2017

Objectives: The present study aims to evaluate existing policy and practice relating to the use of pharmacological treatments with patients suffering from paraphilic disorders who are at risk of committing further sexual offences. Methods: A systematic literature search was conducted to document current legal policies across 26 different countries. In addition, a questionnaire assessing the practice of pharmacological treatment was sent to practitioners involved in the treatment of patients with paraphilic disorders. Results: Legal policies concerning the preconditions of using pharmacological treatments differ considerably between countries, and for most jurisdictions do not exist. Drawing…

MaleInternationalityPsychotherapistParaphilic DisordersAntiandrogensbusiness.industryHealth PolicySexual BehaviorSex OffensesPerspective (graphical)030227 psychiatryPharmacological treatmentAndrogen deprivation therapy03 medical and health sciencesPsychiatry and Mental healthL990 Social studies not elsewhere classified0302 clinical medicineDrug TherapyPractice Guidelines as TopicHumansMedicinebusinessSocial psychologyBiological PsychiatryParaphilic DisordersThe World Journal of Biological Psychiatry
researchProduct

Antiandrogens alone or in combination for treatment of prostate cancer: The European experience

1989

Abstract In Europe, antiandrogens have been used for many years to treat prostate cancer, either as monotherapy or as part of a “combination therapy” with either surgical or chemical castration. However, considerable debate still exists regarding the relative benefits of combination therapy versus antiandrogen monotherapy or castration alone. This article reviews the European experience with antiandrogen therapy, including the personal experiences of the authors.

MaleOncologymedicine.medical_specialtyCombination therapyAntiandrogensmedicine.drug_classUrologyurologic and male genital diseasesAntiandrogenchemistry.chemical_compoundProstate cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineAntiandrogen TherapyChemical castrationRandomized Controlled Trials as TopicGynecologybusiness.industryProstatic NeoplasmsAndrogen Antagonistsmedicine.diseaseCombined Modality TherapyFlutamideEuropeCastrationchemistrybusinessOrchiectomyhormones hormone substitutes and hormone antagonistsUrology
researchProduct

Ethopharmacological studies on the effects of antihormones on rodent agonistic behavior with especial emphasis on progesterone.

1991

The effects of a range of antiandrogens and antiestrogens on conflict behaviors in laboratory rats and mice are reassessed in the light of recent studies applying ethophamacological analyses (recording the full spectrum of behaviors) to such investigations. It is argued that any antihostility properties of the antiandrogen cyproterone acetate are largely a consequence of indirect actions on odor communication, whereas antiestrogens (e.g., tamoxifen and CI 680) seem to have more fundamental motivational effects in addition to communicatory actions. A detailed example of the approach is provided in which progesterone (which can be antiandrogenic) is given to rats paired in different ways. The…

Malemedicine.medical_specialtyRodentLightmedicine.drug_classAntiandrogensCognitive NeuroscienceAntiandrogenStyrenesBehavioral Neurosciencechemistry.chemical_compoundMiceInternal medicinebiology.animalmedicineAgonistic behaviourAnimalsInterpersonal RelationsCyproteroneCyproterone AcetateProgesteronebiologyBody WeightEstrogen AntagonistsCyproterone acetateEstrogen AntagonistsAndrogen AntagonistsOrgan SizeRatsTamoxifenNeuropsychology and Physiological PsychologyEndocrinologychemistryCyproteroneFemalePsychologyhormones hormone substitutes and hormone antagonistsAfter treatmentAgonistic Behaviormedicine.drugNeuroscience and biobehavioral reviews
researchProduct

Studies on the Effects of the Antiandrogen Cyproterone Acetate on Social Encounters Between Pairs of Male Mice

1988

An attempt was made in two experiments to reinvestigate the effects of the antiandrogen cyproterone acetate (CA) on mouse social behavior in a variety of ethologically-assessed paired encounters. The data confirm that CA reduces offense (threat and attack) in animals when both subjects receive the material but that CA has no such action in other pairings. This suggests that CA's major suppressive effect on "hostility" is expressed in mice via a reduction in "attack-promoting" pheromone production. Indeed, there was evidence in the more chronic study that CA, could augment (via a central mechanism?) offense in subjects paired with docile anosmic opponents. Changes in defense were largely res…

Malemedicine.medical_specialtyAntiandrogensmedicine.drug_classMale miceHostilityAntiandrogenMicechemistry.chemical_compoundInternal medicinemedicineAnimalsCyproteroneCyproterone AcetateBehavior AnimalDose-Response Relationship DrugAggressionGeneral NeuroscienceCyproterone acetateAndrogen AntagonistsGeneral MedicineEndocrinologychemistryCyproteronePheromonemedicine.symptomPsychologymedicine.drugInternational Journal of Neuroscience
researchProduct

Testosterone-Lowering Medication and Its Association With Recidivism Risk in Individuals Convicted of Sexual Offenses

2020

For a particular subgroup of individuals with severe paraphilic disorders and a high risk of sexual recidivism, the combination of sex drive–reducing medications and psychotherapy is a promising treatment approach. The present quasi-experimental study aims at comparing differences in clinical characteristics and dynamic risk factors between persons receiving (+TLM, n = 38) versus not receiving (−TLM, n = 22) testosterone-lowering medications (TLMs). Individuals receiving TLM were more frequently diagnosed with paraphilic disorders. Neither the criminal history nor average risk scores differed between the two groups. In the +TLM, Stable-2007 scores showed a stronger decrease after TLM treat…

AdultMaleantiandrogensTreatment durationPsychopathySelf-ControlRisk FactorsGermanyparaphilic disordermedicineHumansTestosteroneAssociation (psychology)General PsychologyAgedAverage riskDuration of TherapyRecidivismParaphilic DisordersSex Offensesrisk assessmentAndrogen Antagonistssexual offender treatmentTestosterone (patch)ArticlesCriminalsMiddle Agedmedicine.diseaseGnRH-agonistsCriminal historyPsychotherapyPsychiatry and Mental healthTreatment OutcomeRecidivismRisk assessmentPsychologyClinical psychologySexual Abuse
researchProduct